Indivior Pharmaceuticals Inc

NASDAQ:INDV

Drug Manufacturers - Specialty & Generic

Healthcare
$36.28 +0.69%

+$0.26 today

Market cap
$4.53B
Beta
1.17
P/E (TTM)
19.1
EPS (TTM)
$2.00
52W Low $13.45High $41.00

Volume 3.65M

Average 2.08M

INDV EBITDA Margin

EBITDA as a percentage of revenue.

Indivior Pharmaceuticals IncNASDAQ: INDV

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 48.1%

EBITDA Margin was 48.1% in Q2 FY2026, up 21.0 pp from a year earlier. On a trailing-twelve-month basis it was 32.8%, up 8.9 pp year over year. Over 3 fiscal years it widened by 29.6 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 3 analysts of 62.3% for the fiscal year ending Dec 2026, up from 24.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
48.1%+8.4 pp QoQ
Last fiscal yearDec 2025
24.5%+17.5 pp YoY
LTMJun 2026
32.8%+8.9 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+21.0 pp+41.8 pp+20.9 pp
1 year+17.5 pp+37.7 pp+20.2 pp
3 years+29.6 pp+42.0 pp+12.4 pp
5 years+47.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
24.5%
Year-over-year change
+17.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How INDV compares with its peers on the latest reported figures

  • INDV's LTM Jun 2026 EBITDA Margin of 32.8% is the 2nd highest of the 4 companies compared; the peer median is 10.2%.
  • Its year-over-year change of +8.9 pp is the 2nd highest of 4, against a peer median of -18.5 pp.
  • Over three fiscal years its change of +29.6 pp compares with a peer median of +14.0 pp.
INDV Competitors Peer median
EBITDA Margin for INDV and competitors
Company Period LTM level YoY 3-year change
COLLCollegium Pharmaceutical, Inc.LTM Mar 202676.6% +26.5 pp+14.0 pp
INDVIndivior Pharmaceuticals IncLTM Jun 202632.8% +8.9 pp+29.6 pp
ALKSAlkermes plcLTM Sep 202610.2% -18.5 pp+17.0 pp
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026-1.9% -26.9 pp-17.1 pp
Peer median (excluding INDV) 10.2%-18.5 pp+14.0 pp

Competitors are the stored peer set for INDV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue791M901M1.09B1.19B1.24B
Cost of Revenue127M151M174M231M246M
Gross Profit664M750M919M957M993M
Gross Margin83.9%83.2%84.1%80.6%80.1%
Research & Development52M74M116M107M97M
Selling, General & Admin431M469M569M618M634M
Operating Expenses451M831M1.08B925M728M
Depreciation & Amortization22M16M15M28M20M
EBITDA238M(46M)(99M)83M304M
EBITDA Margin30.1%-5.1%-9.1%7.0%24.5%
Operating Income213M(81M)(156M)32M265M
Operating Margin26.9%-9.0%-14.3%2.7%21.4%
Interest Income4M19M43M23M22M
Interest Expense26M29M35M41M45M
Other Income / Expenses(23M)(8M)7M(18M)(26M)
Income Before Tax190M(89M)(149M)14M239M
Pre-Tax Margin24.0%-9.9%-13.6%1.2%19.3%
Income Tax Expense(15M)(44M)(20M)11M29M
Net Income205M(44M)(129M)2M210M
Net Margin25.9%-4.9%-11.8%0.2%16.9%
EPS (Basic)1.38(0.37)(0.94)0.021.68
EPS (Diluted)1.31(0.37)(0.91)0.021.64
Weighted Avg Shares145.66M139.01M137.31M132M125M
Weighted Avg Shares (Diluted)154.23M139.01M141.8M133M128M

Indivior Pharmaceuticals Inc

NASDAQ:INDV

Intrinsic Alpha fair value

Locked

Current Price

$36.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.